# Neoadjuvant J591 Treatment for Prostate Cancer

> **NCT02693860** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 8 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** huJ591
- **DRUG:** 89Zr-J591

## Key facts

- **NCT ID:** NCT02693860
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-04
- **Primary completion:** 2017-02-10
- **Final completion:** 2020-02-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02693860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02693860, "Neoadjuvant J591 Treatment for Prostate Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02693860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*